AVLSA
THRD

Atlas Venture Life Science Advisors’s Third Harmonic Bio THRD Stock Holding History

Atlas Venture Life Science Advisors’s Portfolio THRD Stock Details THRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,402,286
Closed -$56.5M – 10
2025
Q2 		$56.5M Hold
10,402,286
– – 8.53% 5
2025
Q1 		$36.1M Hold
10,402,286
– – 6.92% 6
2024
Q4 		$107M Sell
10,402,286
-505,573
-5% -$6.3M 13.06% 4
2024
Q3 		$148M Hold
10,907,859
– – 13.7% 3
2024
Q2 		$142M Hold
10,907,859
– – 14.93% 3
2024
Q1 		$103M Hold
10,907,859
– – 9.5% 5
2023
Q4 		$120M Hold
10,907,859
– – 14.25% 4
2023
Q3 		$69.7M Hold
10,907,859
– – 10.8% 5
2023
Q2 		$52.5M Hold
10,907,859
– – 6.53% 6
2023
Q1 		$44.9M Hold
10,907,859
– – 6.08% 6
2022
Q4 		$46.9M Hold
10,907,859
– – 5.65% 8
2022
Q3 		$207M Buy
+10,907,859
New +$197M 22.84% 1

Other funds holding THRD

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AB
Amalgamated Bank New York $14.5B AUM 44.3% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
Optiver Holding
Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Atlas Venture Life Science Advisors's THRD Position: Q3 2025 in Review

Atlas Venture Life Science Advisors sold out of Third Harmonic Bio (THRD) in Q3 2025, closing a stake of 10,402,286 shares — an estimated $56.5M sold.

Atlas Venture Life Science Advisors first reported a position in THRD in Q3 2022 and held it in 12 quarters. The position peaked at $207M in Q3 2022. 18 funds tracked by Wall St. Rank hold THRD as of Q3 2025.

  • Atlas Venture Life Science Advisors reported no remaining Third Harmonic Bio position as of Q3 2025 after selling out during the quarter.
  • Atlas Venture Life Science Advisors sold 10,402,286 Third Harmonic Bio shares in Q3 2025, an estimated $56.5M.
  • Atlas Venture Life Science Advisors first reported a position in Third Harmonic Bio in Q3 2022 and held it in 12 quarters.
  • Atlas Venture Life Science Advisors's Third Harmonic Bio position peaked at $207M in Q3 2022.
  • 18 funds tracked by Wall St. Rank held Third Harmonic Bio as of Q3 2025.

Based on Atlas Venture Life Science Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.